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Hemagglutination has been used for blood group antigen 
phenotyping for more than a century.1 The exploration of 
the molecular basis of red blood cell (RBC) antigens began 
in the mid-1980s2 and continues today.3–6 RBC and platelet 
antigen genotyping was first proposed on a large scale using 
fluorescence-based detection on glass microarrays, glass 
microplates, or color-encoded beads on a silica support.7–10 
The BloodChip glass microarray was evaluated by multiple 
centers in Europe as part of the BloodGen project.11 Since 
then, RBC genotyping has been adopted by many large donor 
centers,12–16 and many large hospitals now use this testing as 
a routine tool in transfusion medicine.17–19 RBC genotyping 
harnesses the knowledge of the genetic basis of blood group 
antigen expression, with more than 300 antigens in 36 systems 
as of 2015.20 RBC genotyping is based on the knowledge of 
which genes encode the antigens and what genetic variations, 
in many cases single nucleotide polymorphisms (SNPs), are 
present that alter the protein product, resulting in the gain, 
loss, or modification of an antigen.21 The starting material for 
RBC genotyping is typically peripheral blood mononuclear 
cell–derived DNA, although buccal swabs, amniotic fluid–
derived cells, and maternal circulating cell–free fetal DNA are 
also sources of genomic DNA.22 
The advantages of predicting antigen expression through 
DNA-based methods have been reviewed elsewhere and are 
summarized for donors and patients in Table 1 with selected 
references.
In patient care, RBC genotyping is being used most heavily 
in three settings. The first setting is in the alloimmunized 
and/or chronically transfused patient. The frequency of 
alloantibodies is much higher in patients with sickle cell 
disease and thalassemia, where estimates can be as high as 
45 percent35 and 22.6 percent,36 respectively. In these patient 
populations, an extended RBC phenotype, either obtained 
serologically or predicted via RBC genotyping using a human 
erythrocyte antigen (HEA) SNP panel, is becoming the 
standard of care.30,37 Furthermore, in the United States, the use 
of transfusion as a therapeutic modality in sickle cell disease 
Table 1. Utility of RBC genotyping for donors and patients (with selected references)
Scenario Donors Patients References
Predict antigen status when reagents unavailable (e.g., hrB, hrS, Joa, Hy, U)   Reid23
Predict antigen status when weak antigens can be missed serologically (e.g., Fyb, D)   Olsson et al.24;  
Londero et al.25
Predict antigen status when antibody-coated RBCs hamper serologic typing N/A  El Kenz et al.26
Predict antigen status when recent transfusion hampers serologic typing N/A  Reid et al.27
Predict antigen status when variant antigen is suspected to be causing typing discrepancy  
(current vs. historic, reagent 1 vs. reagent 2, method 1 vs. method 2, molecular vs. serologic)
  Arnoni et al.28
Predict antigen status when variant antigen is suspected based on alloimmunization  
(e.g., e+ with anti-e) 
N/A  Reid29
Identify alleles encoding partial antigens when allele matching of donors and patients may be 
considered
  Fasano et al.30
Efficiently identify antigen-negative status for multiple antigens simultaneously   Hashmi et al.9;  
Hashmi et al.31
Predict antigen status in reagent red cells used for antibody screening   Storry et al.32
Determine impact of unlinked genetic factors on antigen expression [e.g., In(Lu)]   Singleton et al.33
Determine zygosity as it relates to HDFN N/A  Pirelli et al.34
Determine zygosity as it relates to reagent red cells used for antibody screening   Storry et al.32
RBC = red blood cell; N/A = not applicable; HDFN = hemolytic disease of the fetus and newborn.
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is on the rise,38 as is prophylactic matching for C, E, and K, 
and, in some institutions, minor blood group antigens.39,40 
The result is an increasing demand for antigen-negative 
blood to serve this patient population. Second, in the setting 
of obstetrics, RHD genotyping can resolve a serologic weak D 
phenotype or inconclusive or discrepant RhD typing. A recent 
commentary in the journal Transfusion has highlighted this 
use and includes a thorough review of the subject.41,42 Use of 
noninvasive screening for RHD by testing cell-free fetal DNA 
from pregnant women has been widely adopted in several 
European countries.43,44 Third, RBC genotyping is a powerful 
tool in patients with warm autoantibodies or a positive direct 
antiglobulin test (DAT) in whom an extended phenotype is 
difficult to obtain serologically.45
In the setting of the donor center, RBC genotyping that 
predicts a panel of human erythrocyte antigens (here referred 
to as an HEA panel) can be beneficial to efficiently identify 
donors lacking multiple common antigens or high-prevalence 
antigens. Rare donor programs such as the American 
Rare Donor Program benefit from the genotyping efforts 
of individual donor centers.46–49 For donor screening, RBC 
genotyping efficiencies can be maximized by using methods 
that offer multi-parallel testing in which multiple samples can be 
interrogated for multiple analytes (often SNPs) simultaneously. 
As the admixture in the United States50 and around the globe 
increases, the incidence of rare donors would be expected to 
decrease such that screening efforts will need to increase. 
The commercially available RBC genotyping products 
differ not only in their format and antigen content, but also their 
license status. The PreciseType™ HEA Molecular BeadChip™ 
(Immucor, Warren, NJ) is the first U.S. Food and Drug 
Administration–licensed RBC genotyping product on the U.S. 
market, and the HEA BeadChip version carries the CE mark. 
The Progenika ID CORE XT is also CE-marked. Until recently, 
proficiency testing for RBC genotyping involved International 
Society for Blood Transfusion (ISBT) workshops51 and ex-
change programs run by testing laboratories (e.g., Consortium 
for Blood Group Genotyping [CBGG],52 INSTAND53) or by 
vendors (Immucor BeadChip).54 There are efforts to develop 
shared reference materials.55 In 2014, the College of American 
Pathology (CAP) launched a CAP survey program for Red Cell 
Antigen Genotyping (RAG).56 AABB has offered accreditation 
of molecular testing laboratories since 2008.57  
This issue of Immunohematology focuses on six RBC 
genotyping methods with the potential to be used as medium- 
to high-throughput screening tools. This is not meant to be 
an exhaustive compilation of the methods in use today but 
instead attempts to give an overview of the methods being 
used in donor centers around the globe. The Immucor and 
Progenika platforms are likely the most common platforms 
in use by donor centers in the United States and Europe; the 
other methods, although not as well disseminated, have the 
potential to be efficient screening methods as donor centers 
worldwide expand their efforts to meet the increasing demand 
for antigen-negative blood. All six methods reviewed here are 
focused on SNP detection—with two using on-bead extension 
followed by fluorescence detection (BeadChip by Immucor, 
ID CORE XT by Progenika), one using extension fragment 
fluorescence detection (SNaPshot by Thermo Fisher), one 
using extension fragment mass determination (HemoID 
Table 2. The six genotyping methods discussed in this issue of Immunohematology
Method Platform (vendor) References Sample capacity
TaqMan genotyping on OpenArray QuantStudio (Thermo Fisher) with 
custom RBC genotyping assays
Hopp et al.58; Denomme  
and Schanen59*
16 assays on 144 samples, 32 assays  
on 96 samples assays, or 64 assays on 
48 samples
Multiplex target-specific PCR 
amplification, allele-specific single 
base primer extension, and MALDI-
TOF MS analysis
MassARRAY with Hemo ID Panels 
(Agena Biosciences)
Meyer et al.16; McBean  
et al.60*
10 multiplex reactions on 33 samples  
per 384-well plate
Single nucleotide primer extension 
minisequencing assay
SNaPshot on ABI Capillary 
Electrophoresis Analyzer (Thermo 
Fisher)
Latini and Castilho61*;  
Latini et al.48
1, 16, 48, or 96 samples (depending  
on capillary number) each with up to  
10 SNPs per multiplex reaction 
Fluidic microarray using XMAP 
technology
Luminex and ID CORE XT (Progenika 
or Grifols)
Goldman et al.62* 6 to 94 samples
Multiplex ligation-dependent probe 
amplification (MLPA)
MLPA SALSA (MRC-Holland 
Amsterdam) on Capillary 
Electrophoresis Analyzer
Veldhuisen et al.63* 3 multiplex reactions on 32 samples per 
96-well plate
Elongation-mediated multiplexed 
analysis of polymorphisms (eMAP)
Array Imaging System (AIS) with HEA 
BeadChip (Immucor)
Hashmi et al.31;  
Paccapelo et al.64*
1 multiplex reaction on 6 or 94 samples
*Article included in this issue. RBC = red blood cell; PCR = polymerase chain reaction; SNP, single nucleotide polymorphism.
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by Agena), one using multiplex ligation-dependent probe 
amplification (MLPA) (SALSA by MRC-Holland), and the 
sixth using TaqMan genotyping on OpenArray (QuantStudio 
by ThermoFisher). All but one (TaqMan) use multiplex 
polymerase chain reaction to interrogate multiple blood 
group antigen genes simultaneously. All require specialized 
instrumentation, with two using capillary electrophoresis 
systems (MLPA and SNaPshot). Table 2 lists the six methods 
with their capacity and associated references. The authors 
were asked to include in their article the scientific principle of 
the approach, what instrumentation and software is required, 
the potential throughput, whether the platform offers the user 
the ability to customize the variants interrogated, and whether 
the assays have been validated. Molecular immunohematology 
laboratories can review the strengths and limitations of these 
methodologies and the experiences of those centers that have 
implemented these approaches and determine which of these 
methods might meet their needs and that of their population.
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